Skip to content
Triangle logo TriangleGet started
← Study library

NCT01426880 · CITED IN SOURCE DOCUMENTS

Addition of Carboplatin to Neoadjuvant Therapy for Triple-negative and HER2-positive Early Breast Cancer

An NCI or FDA source cites this study. A citation does not establish that it applies to an individual diagnosis.

Phase
PHASE2, PHASE3
Status at capture
COMPLETED
Registry last update
2016-02-15

Study participants with primary breast cancer will receive a standard chemotherapy with an anthracycline and a taxane as well as trastuzumab in case of HER2-positive tumors at doses and duration in concordance to current treatment guidelines. Patients will be receive and benefit in addition currently not in the neoadjuvant setting registered medication as lapatinib or bevacizumab of which significant increases of cure (pCR) rates have been reported in previous phase III studies. Patients randomized to carboplatin will receive in addition to the described backbone therapies a potentially active agent which suggested synergy of efficacy with chemotherapies as well as targeted agents. Patients might have the risk of an increase in toxicities due to the added agents and will have additional burden due to investigations required for study participation. However, due to the severity of the underlying disease and the high risk of relapse and death due to the stage of disease, this increase in toxicity and burden appears less relevant compared to the potential higher efficacy and finally cure rate by the incorporated treatments.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

No posted result sections were captured. Registered plans do not establish that a treatment works.

Who could take part
eligibility Criteria
Inclusion Criteria: * 1.Written informed consent for all study procedures according to local regulatory requirements prior to beginning specific protocol procedures. * 2.Complete baseline documentation must be submitted via Medcodes® and approved by GBG Forschungs GmbH. * 3.Unilateral or bilateral primary carcinoma of the breast, confirmed histologically by core biopsy. Fine-needle aspiration is not sufficient. Incisional biopsy is not allowed. In case of bilateral cancer, the investigator has to decide prospectively which side will be evaluated for the primary endpoint. * 4.Tumor lesion in the breast with a palpable size of ≥ 2 cm or a sonographical size of ≥ 1 cm in maximum diameter. The lesion has to be measurable in two dimensions, preferably by sonography. In case of inflammatory disease, the extent of inflammation can be used as measurable lesion. * 5.Patients should be in the following stages of disease: cT2 - cT4a-d or cT1c and cN+ or pNSLN+ * 6.In patients with multifocal or multicentric breast cancer, the largest lesion should be measured. * 7.Centrally confirmed ER/PR/HER-2 and Ki-67 status detected on core biopsy. ER/PR positive is defined as \>1% stained cells and HER2-positive is defined as HercepTest IHC 3+ or FISH ratio ≥ 2.2. Formalin-fixed, paraffin-embedded (FFPE) breast tissue from core biopsy has therefore to be sent to the Dept. of Pathology at the Charité, Berlin prior to randomization. * 8.Age ≥ 18 years. * 9.Karnofsky Performance status index ≥ 80%. * 10.Normal cardiac function must be confirmed by ECG and cardiac ultrasound (LVEF or shortening fraction) within 3 months prior to randomization. LVEF must be above 55%. * 11.Laboratory requirements: Hematology * Absolute neutrophil count (ANC) ≥ 2.0 x 109 / L and * Platelets ≥ 100 x 109 / L and * Hemoglobin ≥ 10 g/dL (≥ 6.2 mmol/L) Hepatic function * Total bilirubin \< 1.5x UNL and * ASAT (SGOT) and ALAT (SGPT) ≤ 1.5x UNL and * Alkaline phosphatase ≤ 2.5x UNL. Renal function * Creatinine ≤ 175 µmol/L (2 mg/dL) \< 1.5x UNL * Proteinuria: Urine dipstick for proteinuria \< 2+. Patients discovered to have ≥ 2+ proteinuria on dipstick urinalysis should undergo a 24-hour urine collection and must demonstrate ≤ 1 g of protein in 24 hours. If creatinine is between 140 - 175 umol/L (1.6-2.0 mg/dL), the creatinine clearance (calculated or measured) should be ≥ 45 mL/min. * 12.Negative pregnancy test (urine or serum) within 14 days prior to randomization for all women of childbearing potential. * 13.Complete staging work-up within 3 months prior to randomization. All patients must have bilateral mammography, breast ultrasound (≤ 21 days), breast MRI (optional), chest X-ray (PA and lateral), abdominal ultrasound or CT scan or MRI, and bone scan done. In case of positive bone scan, bone X-ray (or CT or MRI) is mandatory. Other tests may be performed as clinically indicated. * 14.Patients must be available and compliant for central diagnostics, treatment and follow-up. Exclusion Criteria: 1. Prior chemotherapy for any malignancy. 2. Prior radiation therapy for breast cancer. 3. Pregnant or lactating patients. Patients of childbearing potential must implement adequate non-hormonal contraceptive measures (barrier methods, intrauterine contraceptive devices, sterilization) during study treatment. 4. Inadequate general condition (not fit for anthracycline-taxane-targeted agents-based chemotherapy). 5. Previous malignant disease being disease-free for less than 5 years (except CIS of the cervix and non-melanomatous skin cancer). 6. Known or suspected congestive heart failure (\>NYHA I) and / or coronary heart disease, angina pectoris requiring antianginal medication, previous history of myocardial infarction, evidence of transmural infarction on ECG, uncontrolled or poorly controlled arterial hypertension (i.e. BP \>160 / 90 mm Hg under treatment with two antihypertensive drugs), rhythm abnormalities requiring permanent treatment, clinically significant valvular heart disease. 7. Previous thromboembolic event (except when thrombophily screening is negative). 8. Known hemorrhagic diathesis or coagulopathy with increased bleeding risk. 9. History of significant neurological or psychiatric disorders including psychotic disorders, dementia or seizures that would prohibit the understanding and giving of informed consent 10. Pre-existing motor or sensory neuropathy of a severity ≥ grade 2 by NCI-CTC criteria v 4.0. 11. Currently active infection. 12. Active peptic ulcer. 13. Incomplete wound healing or unhealed bone fracture. 14. Disease significantly affecting gastrointestinal function, e.g. malabsorption syndrome, resection of the stomach or small bowel, ulcerative colitis. 15. History of abdominal fistula or any grade 4 non-gastrointestinal fistula, gastrointestinal perforation or intra-abdominal abscess within 6 months of enrolment. 16. Severe pulmonary condition / illness. 17. Major surgery within the last 28 days or anticipation of the need for major surgery during study treatment with bevacizumab. Minor surgeries including insertion of an indwelling catheter or sentinel lymph node biopsy within 24 h prior to chemotherapy. 18. Definite contraindications for the use of corticosteroids except inhalative corticoids. 19. Known hypersensitivity reaction to one of the compounds or incorporated substances used in this protocol; 20. Concurrent treatment with: * chronic corticosteroids unless initiated \> 6 months prior to study entry and at low dose (≤ 10 mg methylprednisolone or equivalent). * sex hormones. Prior treatment must be stopped before study entry. * virostatic agents like sorivudine or analogs like brivudine, concurrent treatment with aminoglycosides. * anticoagulants: heparin, warfarin as well as acetylic acid (e.g. Aspirin®) at a dose of \> 325 mg/day or clopidogrel at a dose of \> 75 mg/day. * other experimental drugs or any other anti-cancer therapy. * drugs recognized as being strong inhibitors or inducers of the isoenzyme CYP3A, e.g. Rifabutin, Rifampicin, Clarithromycin, Ketoconazole, Itraconazole, Ritonavir, Telithromycin, Erythromycin, Verapamil, Diltiazem within the last 5 days or the expected need for these treatments during study participation. 21. Participation in another clinical trial with any investigational, not marketed drug within 30 days prior to study entry. 22. Male patients.
healthy Volunteers
false
minimum Age
18 Years
sex
FEMALE
std Ages
  1. ADULT
  2. OLDER_ADULT
Treatment arms and interventions
arm Groups
  1. description
    Carboplatin AUC 2 min/mL weekly, infusion will be used as Add-on to the background therapy (same as comparator arm)
    intervention Names
    1. Drug: Carboplatin
    2. Drug: background treatment
    label
    Carboplatin + background treatment
    type
    EXPERIMENTAL
  2. description
    background treatment with NLPD (Myocet), Paclitaxel, Herceptin (Trastuzumab fpr Her2 pos), Tyverb (Lapatinib for Her2 pos), Avastin (Bevacizumab for triple negative) agents are used according to marketed formulation via normal procedures at each site and applied according to recommendations of the manufacturers.
    intervention Names
    1. Drug: background treatment
    label
    background treatment only
    type
    ACTIVE_COMPARATOR
interventions
  1. arm Group Labels
    1. Carboplatin + background treatment
    description
    Carboplatin, AUC, 2 min/mL weekly, infusion
    name
    Carboplatin
    other Names
    1. platin
    type
    DRUG
  2. arm Group Labels
    1. Carboplatin + background treatment
    2. background treatment only
    description
    background treatment according to standards fpr triple negative and Her2pos breast cancer patients Paclitaxel: 80 mg/m² i.v. given weekly on day 1 q day 8 for 18 weeks. NPLD (Myocet®): 20 mg/m² weekly on day 1 q day 8 for 18 weeks Trastuzumab (only for HER2-positive patients): Loading dose: 8 mg/kg, Maintenance dose: 6 mg/kg, day 1 q day 22 for 6 cycles. Post-surgery: up to a total duration of 1 year according to current AGO guidelines Lapatinib 750 mg/day p.o. continuously for 18 weeks; in case of good tolerability (no CTC grade II toxicity except alopecia and nausea/vomiting) during the first cycle the dose may be escalated to 1000 mg. Bevacizumab: 15 mg/kg i.v., day 1 q day 22 for 6 cycles (only in TNBC patients).
    name
    background treatment
    other Names
    1. Avastin
    2. Paclitaxel
    3. Myocet
    4. Lapatinib
    5. Bevacizumab
    type
    DRUG
Study design
allocation
RANDOMIZED
intervention Model
PARALLEL
masking Info
masking
NONE
primary Purpose
TREATMENT
Enrollment
count
595
type
ACTUAL
Registered outcome plans (not posted results)
primary Outcomes
  1. description
    Pathological response will be assessed considering all removed breast and lymphatic tissues from all surgeries. Surgery takes place shortly after the 18 weeks (six 3-week cycles) chemotherapy treatment. No microscopic evidence of residual viable tumor cells in all resected specimens of the breast and axilla meets the primary endpoint.
    measure
    Pathological complete response of breast and lymph nodes (ypT0 ypN0; primary endpoint)
    time Frame
    24 weeks (time window -3 weeks)
secondary Outcomes
  1. measure
    1.ypT0/is ypN0; ypT0; ypT0/is; ypN0, and regression grades
    time Frame
    24 weeks (time window -3 weeks)
  2. description
    To determine the response rates of the breast tumor and axillary nodes based on physical examination and imaging tests. (sonography, mammography, or MRI) after treatment in both arms.
    measure
    Clinical and imaging response
    time Frame
    24 weeks (time window -3 weeks)
  3. description
    LRRFS, RRFS, LRFS, DDFS, IDFS and OS are defined as the time period between registration and first event and will be analyzed after the end of the study by referring to data from GBG patient's registry.
    measure
    loco-regional invasive recurrence free survival (LRRFS), regional recurrence free survival (RRFS), local recurrence free survival (LRFS), distant-disease- free survival (DDFS), invasive disease-free survival (IDFS), and overall survival (OS)
    time Frame
    5 years
  4. description
    Tolerability and Safety: Descriptive statistics for the 4 treatments will be given on the number of patients whose treatment had to be reduced, delayed or permanently stopped
    measure
    Tolerability and Safety
    time Frame
    during treatment 18 weeks
  5. description
    • To assess the pCR rates per arm separately in patients with triple-negative tumors and HER2-positive tumors.
    measure
    pCR rates per arm
    time Frame
    24 weeks (time window -3 weeks)
  6. description
    To determine the breast and axilla conservation rate after each treatment.
    measure
    Breast and axilla conservation rate
    time Frame
    24 weeks (time window -3 weeks)
  7. description
    To determine the pCR rate and local recurrence free survival (LRFS) in patients with a clinical complete response (cCR) and a negative core biopsy before surgery.
    measure
    pCR rate and local recurrence free survival in correlation to clinical complete response and negative core biopsy before surgery
    time Frame
    5 years
  8. description
    To determine the response rates of the breast tumor and axillary nodes based on physical examination and imaging tests. (sonography, mammography, or MRI) after treatment in both arms.
    measure
    Clinical and imaging response
    time Frame
    6 weeks
  9. description
    To assess the pCR rate in patients with a clinical complete response and a negative core biopsy before surgery.
    measure
    PCR rate in patients with a clinical complete response and a negative core biopsy
    time Frame
    24 weeks (time window -3 weeks)
  10. description
    To assess regional recurrence free survival (RRFS) in patients with initial node-positive axilla converted to negative at surgery and treated with sentinel node biopsy alone.
    measure
    Regional recurrence free survival (RRFS)in patients with initial node-positive axilla
    time Frame
    until event occurs - no events for cured patients
  11. description
    To examine and compare pre-specified molecular markers such as BRCA1-mRNA, P53, ALDH1, p4E-BP1, IL-8 metagene, B-Cell metagene as well as exploratory analyses and lymphocyte infiltration on core biopsies before and surgical tissue after end of chemotherapy. The aim is to identify potential predictive short and long term parameters.
    measure
    Examination and comparison of molecular markers
    time Frame
    Baseline, 6 weeks and 24 weeks
  12. description
    To assess, characterize, and correlate circulating tumor cells and proteins with the effect of treatment.
    measure
    CTC Substudy
    time Frame
    Baseline, 6 weeks and 24 weeks
Full study description
brief Summary
Study participants with primary breast cancer will receive a standard chemotherapy with an anthracycline and a taxane as well as trastuzumab in case of HER2-positive tumors at doses and duration in concordance to current treatment guidelines. Patients will be receive and benefit in addition currently not in the neoadjuvant setting registered medication as lapatinib or bevacizumab of which significant increases of cure (pCR) rates have been reported in previous phase III studies. Patients randomized to carboplatin will receive in addition to the described backbone therapies a potentially active agent which suggested synergy of efficacy with chemotherapies as well as targeted agents. Patients might have the risk of an increase in toxicities due to the added agents and will have additional burden due to investigations required for study participation. However, due to the severity of the underlying disease and the high risk of relapse and death due to the stage of disease, this increase in toxicity and burden appears less relevant compared to the potential higher efficacy and finally cure rate by the incorporated treatments.
detailed Description
Anthracycline/taxane based combination chemotherapy of at least 18 weeks represents the standard of care in the neoadjuvant setting. In HER2-positive disease trastuzumab is given simultaneously to chemotherapy. Recent data from the Neo-Altto and Neosphere trials suggest that a dual blockage of the HER2 receptor with e.g. trastuzumab and lapatinib reach significantly higher pCR rates than trastuzumab alone and should therefore represent the treatment back-bone of new neoadjuvant trials. A preplanned subgroup analysis of the GeparQuinto study demonstrated that in TNBC the addition of bevacizumab resulted in a significant increase of pCR rates (HR 1.4). Having a better cardiac tolerability profile compared to conventional anthracyclines, the non-pegylated liposomal encapsulated doxorubicin (NPLD) Myocet® might provide the possibility to combine taxane, anthracycline, platinum salt as well with targeted agents as double HER2 blockage or bevacizumab.
Source references
references
  1. citation
    Denkert C, von Minckwitz G, Brase JC, Sinn BV, Gade S, Kronenwett R, Pfitzner BM, Salat C, Loi S, Schmitt WD, Schem C, Fisch K, Darb-Esfahani S, Mehta K, Sotiriou C, Wienert S, Klare P, Andre F, Klauschen F, Blohmer JU, Krappmann K, Schmidt M, Tesch H, Kummel S, Sinn P, Jackisch C, Dietel M, Reimer T, Untch M, Loibl S. Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers. J Clin Oncol. 2015 Mar 20;33(9):983-91. doi: 10.1200/JCO.2014.58.1967. Epub 2014 Dec 22.
    pmid
    25534375
    type
    RESULT
  2. citation
    Loibl S, von Minckwitz G, Schneeweiss A, Paepke S, Lehmann A, Rezai M, Zahm DM, Sinn P, Khandan F, Eidtmann H, Dohnal K, Heinrichs C, Huober J, Pfitzner B, Fasching PA, Andre F, Lindner JL, Sotiriou C, Dykgers A, Guo S, Gade S, Nekljudova V, Loi S, Untch M, Denkert C. PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (her2) therapy in primary HER2-overexpressing breast cancer. J Clin Oncol. 2014 Oct 10;32(29):3212-20. doi: 10.1200/JCO.2014.55.7876. Epub 2014 Sep 8.
    pmid
    25199759
    type
    RESULT
  3. citation
    von Minckwitz G, Schneeweiss A, Loibl S, Salat C, Denkert C, Rezai M, Blohmer JU, Jackisch C, Paepke S, Gerber B, Zahm DM, Kummel S, Eidtmann H, Klare P, Huober J, Costa S, Tesch H, Hanusch C, Hilfrich J, Khandan F, Fasching PA, Sinn BV, Engels K, Mehta K, Nekljudova V, Untch M. Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial. Lancet Oncol. 2014 Jun;15(7):747-56. doi: 10.1016/S1470-2045(14)70160-3. Epub 2014 Apr 30.
    pmid
    24794243
    type
    RESULT
  4. citation
    Hahnen E, Lederer B, Hauke J, Loibl S, Krober S, Schneeweiss A, Denkert C, Fasching PA, Blohmer JU, Jackisch C, Paepke S, Gerber B, Kummel S, Schem C, Neidhardt G, Huober J, Rhiem K, Costa S, Altmuller J, Hanusch C, Thiele H, Muller V, Nurnberg P, Karn T, Nekljudova V, Untch M, von Minckwitz G, Schmutzler RK. Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer: Secondary Analysis of the GeparSixto Randomized Clinical Trial. JAMA Oncol. 2017 Oct 1;3(10):1378-1385. doi: 10.1001/jamaoncol.2017.1007.
    pmid
    28715532
    type
    DERIVED
Source notices and limitations
    Discovery and provenance
    1. release id
      ctgov-registry-7ad944f6deaf1f5cd6122126
      edge id
      nct-edge-d78c0d682de477c3945b
      requested nct id
      NCT01426880
      primary nct id
      NCT01426880
      source kind
      nci_explicit_reference_or_link
      source record id
      Source null
      source file sha256
      862f78faa9e4cbedc19f9ffcaeba97e029ba51b72bb3b81fc67aa8b6adf96904
      payload sha256
      8d30c24a2bb3daab581133262783733fbd949024bb6f2b72e4601aac157d6b6b
      payload
      clinical indication matching status
      not_inferred
      end exclusive
      true
      id
      nct-edge-d78c0d682de477c3945b
      link basis
      explicit_NCT_identifier_in_acquired_source
      nct id
      NCT01426880
      occurrences
      1. context exact
        /taxane&#8211;based chemotherapy regimen in patients with TNBC):</p> <div class="pdq-content-list"><ol id="_3462"><li>In the <a href="/clinicaltrials/NCT01426880">GeparSixto</a> trial (NCT01426880), carboplatin was added to an anthracycline/taxane&#8211;based backbone.[<a href="#cit/section_6.103">103</a>][<a href="/Com
        end
        383357
        exact text
        NCT01426880
        start
        383346
      2. context exact
        gimen in patients with TNBC):</p> <div class="pdq-content-list"><ol id="_3462"><li>In the <a href="/clinicaltrials/NCT01426880">GeparSixto</a> trial (NCT01426880), carboplatin was added to an anthracycline/taxane&#8211;based backbone.[<a href="#cit/section_6.103">103</a>][<a href="/Common/PopUps/popDefinition.aspx?id=81
        end
        383392
        exact text
        NCT01426880
        start
        383381
      offset unit
      unicode_code_points
      source file
      /tmp/cancer-full-research/nci/raw/29bf1e5a1d739974ed.html
      source file sha256
      862f78faa9e4cbedc19f9ffcaeba97e029ba51b72bb3b81fc67aa8b6adf96904
      source json pointer
      Source null
      source kind
      nci_explicit_reference_or_link
      source record id
      Source null
      source retrieved at
      2026-09-09T23:21:35.419733+00:00
      source string basis
      UTF-8_text_with_universal_newline_translation
      source string sha256
      536430925e3b0008edd3fb69a869d5645bd6b6dc5c84c21ddf1b3e24f089874c
      source title
      Breast Cancer Treatment (PDQ®)–Health Professional Version
      source update dates
      1. context
        Updated: April 25, 2025
        datetime
        2025-04-25T12:00:00Z
        display
        April 25, 2025

    Preserved source evidence · Not medical advice